NEW ORLEANS and CARLSBAD, Calif., Nov. 6
/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS)
announces the following webcast:
What: Isis' cardiovascular program review of development and
late-stage research candidates, including presentations
from:
-- Dr. Erik Stroes reporting top line data from an ongoing
Phase 2 mipomersen liver imaging study
-- Dr. Evan Stein providing an update on an open-label
extension study of mipomersen in subjects with familial
hypercholesterolemia
When: Monday, November 10, 2008, at 6:00 p.m. CT (4:00 p.m.
PT/7:00 p.m. ET)
Where: http://www.isispharm.com
How: Live on the Internet. Simply log onto the website listed
above.
Contacts: Kristina Lemonidis
Associate Director, Corporate Development
Isis Pharmaceuticals, Inc.
(760) 603-2490
Amy Blackley, Ph.D.
Manager, Corporate Communications
Isis Pharmaceuticals, Inc.
(760) 603-2772
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and ha
'/>"/>
| SOURCE Isis Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |